This website is for UK Healthcare Professionals only

PSORIATIC ARTHRITIS

RINVOQ, the first ever once-daily oral JAK inhibitor for the treatment of active PsA, AS and RA1

 

Improvement in signs and symptoms as measured by ACR20 from as early as
Week 2 and maintained to Week 56, with significantly greater improvement in ACR20 vs placebo at Week 12 and non-inferiority vs adalimumab in ACR20 response at
Week 12.*1,3,4

Significantly more patients treated with RINVOQ achieved PASI 75 at Week 16 vs placebo. 

Significantly more patients achieved resolution of enthesitis and minimal disease activity at Week 24 vs placebo.1,3,5

The safety profile of RINVOQ in PsA was consistent with previously reported results in rheumatoid arthritis and no new significant safety signals were
identified.1,3-8

*Primary endpoint was the proportion of patients achieving ACR20 response with RINVOQ vs placebo at Week 12.3

RINVOQ PsA Overview

NICE Publishes Positive Technology Appraisal Guidance (TAG) for RINVOQ for treating active psoriatic arthritis in adults2

RINVOQ, alone or with methotrexate, is recommended as an option for treating active psoriatic arthritis in adults whose disease has not responded well enough to DMARDs or who cannot tolerate them. 

It is recommended only if they have peripheral arthritis with 3 or more tender joints and 3 or more swollen joints and: 

• they have had 2 conventional DMARDs and at least 1 biological DMARD or 

• TNF-alpha inhibitors are contraindicated but would otherwise be considered. 

RINVOQ is recommended only if AbbVie provides it according to the commercial arrangement.

ACR20 = Improvement of at least 20% in the American College of Rheumatology core criteria; AS = Ankylosing Spondylitis; DMARDs = Disease-Modifying Antirheumatic Drugs; JAK = Janus Kinase; MTX = Methotrexate; NICE = National Institute for Health and Care Excellence; PASI 75 = Psoriasis Area and Severity Index 75% improvement; PsA = Psoriatic Arthritis; RA = Rheumatoid Arthritis; TAG = Technology Appraisal Guidance; TNF = Tumour Necrosis Factor.

References

  1. RINVOQ SmPC.
  2. NICE (2022) Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs; Technology Appraisal Guidance; TA768. Available at: https://www.nice.org.uk/guidance/ta768 (accessed February 2022).
  3. McInnes IB, et al. N Engl J Med 2021;384;1227-39.
  4. McInnes IB, et al. RMD Open 2021;7:e001838.
  5. Nash P, et al. Arthritis Rheumatol 2020; 72(suppl. 10):POS1035.
  6. van der Heijde D, et al. Lancet 2019;394:2108-2117.
  7. Deodhar A, et al. Arthritis Rheumatol 2020;72(suppl. 10):2023.
  8. Cohen SB, et al. EULAR E-Congress 2021;POS0220. 

UK-UPAD-220201. Date of preparation: August 2022.

Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com